Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape.

Expert opinion on pharmacotherapy2025PMID: 41351384

View on PubMed DOI: 10.1080/14656566.2025.2601060

Plain Language Summary

Comparative review of semaglutide and tirzepatide for obesity management, synthesizing clinical trial data from STEP and SURMOUNT programs, head-to-head evidence from SURMOUNT-5, differential effects on weight, glycemia, cardiometabolic markers, tolerability, and cost, with guidance on clinical decision-making between the two agents. Aims to support precision prescribing. Provides prescribers with a practical decision-making framework for choosing between semaglutide and tirzepatide—addressing the common clinical question of whether tirzepatide's superior weight loss justifies its different cost, tolerability profile, and indication differences relative to semaglutide.

Abstract

BACKGROUND: Obesity is a chronic disease with significant global health repercussions. GLP-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1 receptor agonists (GIP/GLP-1RAs) are now established as evidence-based options for long-term obesity management. This review compares semaglutide and tirzepatide aims to support precise, equitable, and durable care for people with the disease of obesity. AREAS COVERED: This review provides clinicians with a comparative analysis of semaglutide (Ozempic) and tirzepatide (Mounjaro) in obesity management. We synthesize data from pivotal clinical trials (STEP, SELECT, SURMOUNT, SUMMIT) to guide evaluation of weight loss, metabolic, and cardiovascular benefits. Mechanistic differences, tolerability, and real-world implementation, including patient access and sustainability. The literature search was conducted using PubMed and Google Scholar and through a review of major international cardiology and endocrinology publications from 2020 to 2025. EXPERT OPINION: Semaglutide and tirzepatide represent foundational options in contemporary obesity pharmacotherapy. Semaglutide offers robust cardiovascular protection; tirzepatide yields greater weight loss and broad metabolic benefits. Both agents require clinicians to reconceptualize obesity as a chronic disease needing ongoing pharmacological management.

Authors

Mondoh, Alvin; Crotty, Michael; le Roux, Carel W

Keywords

GLP-1 receptor agonistsObesitysemaglutideside effectstirzepatideweight loss